Richard E. Champlin

TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.

TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.

TL;DR: It is demonstrated that, for the purpose of anticancer therapy, bone marrow-derived mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites and that the tumor microenvironment preferentially promotes the engraftment of MSCs as compared with other tissues.

TL;DR: Injected MSC-IFN-beta cells suppressed the growth of pulmonary metastases, presumably through the local production of IFN- beta in the tumor microenvironment, and may be an effective platform for the targeted delivery of therapeutic proteins to cancer sites.

TL;DR: All six recipients of sex-mismatched transplants showed evidence of complete hematopoietic donor chimerism and the presence of donor cells in the biopsy specimens did not seem to depend on the intensity of tissue damage induced by graft-versus-host disease.